Sacituzumab tirumotecan for SMARCB1-deficient kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of advanced or metastatic renal medullary carcinoma (RMC) that has lost the SMARCB1 protein.
- Your cancer must have gotten worse after at least one prior treatment.
- You need to be well enough for daily activities (ECOG score of 0 or 1) and be 18 or older.
- You must have at least one tumor that can be measured on a scan (like CT or MRI).
- Your liver, kidney, and blood cell counts must meet certain minimum levels.
- You must agree to use effective birth control if applicable, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sacituzumab tirumotecan, in people with squamous cell carcinoma of the anus or rectum that has spread or cannot be removed. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new drug (sacituzumab tirumotecan) for people with rare types of kidney or bladder cancer that have spread. The drug targets a protein called TROP-2 on cancer cells. The goal is to see if it can shrink tumors or slow the cancer when other treatments have stopped working or are not available.
This study tests a new drug called sacituzumab tirumotecan for people with thymic carcinoma that has spread or come back after platinum-based chemotherapy. The drug targets a protein on cancer cells to deliver chemotherapy directly to them, which may help shrink tumors or slow their growth.
Hear when a new Phase II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.